FDA indications According to the Prescribing Information, the wording of the FDA indications for semaglutide injection (Wegovy ) is as follows (the emphasis below in red has been added by us): WEGOVY is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated in combination with a reduced calorie diet and increased physical activity: to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight
Its available under the brand names Wegovy, Ozempic, and Rybelsus
Comparing tirzepatide 7.5 mg to semaglutide equivalent doses Researchers who have used semaglutide before switching to tirzepatide often want to know how the doses compare
For patients with obesity or mainly seeking a weight loss injection, Wegovy is the only one approved by the FDA, while Ozempic and Rybelsus are focused more on blood sugar control
While TB-500 is banned in competitive sports, it continues to be studied for its potential in promoting angiogenesis, tissue repair, and modulation of actin-binding proteins
Both UHC and Cigna have PBM standard formularies that exclude weight-loss GLP-1s, but the mechanics differ
